Incannex Healthcare is a clinical-stage biopharmaceutical company developing oral drug candidates for serious chronic conditions. The company has no approved products and generates no revenue; its entire value depends on clinical and regulatory success. Incannex has three lead programs. IHL-42X is an oral fixed-dose combination of dronabinol and acetazolamide for obstructive sleep apnea, targeting patients who cannot tolerate CPAP devices. The Phase 2 RePOSA trial met its primary endpoint in July 2025, and Incannex is preparing for an End of Phase 2 FDA meeting ahead of a Phase 3 trial. PSX-001 is an oral synthetic psilocybin treatment for generalized anxiety disorder, administered alongside structured psychotherapy. The Phase 2 PsiGAD1 trial met its primary endpoint in August 2025, with patients achieving an average 12.8-point HAM-A score reduction and a 24% full remission rate, and Incannex plans to initiate a Phase 2b trial in the U.S. and U.K. in 2026. IHL-675A is an oral combination of synthetic CBD and hydroxychloroquine for rheumatoid arthritis; its Australian Phase 2 trial was terminated due to recruitment failures, and the program is being reset for a U.S.-based study. Each candidate pursues the FDA's 505(b)(2) pathway, which allows reliance on existing data from already-approved component drugs. Incannex has 12 employees and outsources all manufacturing and clinical operations to third-party contractors. The company's path to revenue requires completing Phase 3 trials and obtaining FDA approval, which remains years away.